Shi J, Yu T, Song K, Du S, He S, Hu X, et al
This agility far outpaces many other regions (for example, comparable approvals can take 34 months in China)
In November 2023, tirzepatide for chronic weight management was approved as Zepbound, with SURMOUNT trial data showing mean weight loss of roughly 21% at the 15 mg dose over 72 weeks
These findings reinforce the notion that metabolic dysfunction, and obesity in particular, is not merely a comorbidity but an active modifier of PsA pathophysiology and treatment outcomes
Compounded medications are not FDA-approved and are prepared by licensed compounding pharmacies
Whether the FDA ultimately recommends adding these peptides to a bulks list or not, this week's meeting should prompt a broader conversation